The Lesson Of Jevtana: With A Survival Advantage, All Things Are Possible
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
The expedited review and approval of Sanofi-Aventis’ oncologic Jevtana (cabazitaxel) shows the power of a clearly demonstrated survival advantage to overcome regulatory hurdles.